Re-suturing after primary endoscopic sleeve gastroplasty (ESG) for obesity

López-Nava, Gontrand; Asokkumar, Ravishankar; Negi, Anuradha; Normand, Enrique; Bautista, Inmaculada

doi:10.1007/s00464-020-07666-6

Cited by 27 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings lend support to the hypothesis that POSE-2 interferes with gastric motility. Unlike the existing endoscopic gastroplasty procedures, we demonstrated that the POSE-2 plications were durable at 1 year [14]. The large plications (6.6 cm) maintained a gastric length reduction at 1 year that was similar to the results of the pilot study [7] and restricted the distensibility, which may further contribute to early satiation.…”

Section: Discussionsupporting

confidence: 49%

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction POSE-2 procedure shortens and narrows the stomach using multiple full-thickness plications in the gastric body. We studied the efficacy and safety of POSE-2 for obesity at 1-year in a real-world setting. Methods We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary outcome was to evaluate the %total body weight loss (%TBWL) at 1-year. Our secondary outcome was to assess the safety and durability. We used linear mixed model analysis. RESULTS: Forty-six patients completed 1-year. The rest are in various phases of follow-up. The mean(SD) age and BMI was 49.3(10.2) years and 38.2(6.6) kg/m2, respectively. The technical success rate was 98.7% (n=74). The mean(SD) TBWL, %TBWL, and the BMI decline at 1-year were 20(12.7) kg, 17.8(9.5)%, 7(4.3) kg/m2. Adverse events occurred in 4 patients. The average length of stay was 1-day. Endoscopy at 1-year in 15 patients showed intact sutures and a reduction in gastric length compared to baseline [35.7(3.5) cm vs. 26.9(5.3) cm, p<0.001] CONCLUSION: POSE-2 induced significant weight loss at 1-year. It is safe, durable and required only a short hospital stay.

show abstract

Section: Discussionsupporting

confidence: 49%

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…To further improve or maintain the effect of weight loss, ESG can be repeated if necessary or performed as an effective revision for surgical weight loss surgery. [ 52 , 53 ] Other than the control of caloric intake, the pathophysiological mechanisms of ESG still need to be further explored. [ 54 ] A meta-analysis of 1859 obese patients who underwent ESG showed that at 6 months, 12 months, and 24 months after surgery, the average %TWL was 14.86%, 16.43%, and 20.01%, respectively, and the average %EWL was 55.75%, 61.84%, and 60.40%, respectively.…”

Section: Endoscopic Bariatric Techniquesmentioning

confidence: 99%

From surgery to endoscopy: the evolution of the bariatric discipline

Wei

Zhang

2022

Chinese Medical Journal

View full text Add to dashboard Cite

Obesity, with its increasing morbidity and prevalence, is now a worldwide public health problem. Obesity and its related comorbidities impose a heavy burden on societal health and the economy. The practice of bariatric surgery has evolved from its early surgical procedures, many of which are no longer routine operations. With clinical practice, research, and experience, bariatric surgery has gradually become an important last resort for the control of weight and obesity-related metabolic diseases in moderately and severely obese patients. However, there is still room for further improvements in bariatric surgical procedures, especially with regard to long-term issues and complications. Endoscopic weight loss technology has developed rapidly in recent years. The advantages of this technology include minimal invasiveness, an obvious weight loss effect, and few complications, thus filling the gap between medications and lifestyle adjustments and surgical treatment of obesity. Endoscopic weight loss technology may even replace surgical bariatric procedures. This review summarized the current status of bariatric metabolic surgery and newly developed bariatric endoscopic procedures.

show abstract

“…In another retrospective study, QoL and mental health outcomes were significantly improved after ESG [57]. Lopez-Nava et al [58] performed redo ESG in 7% of their ESG patients for weight loss failure (WF), weight regain (WR), or weight plateau (WP). R-ESG carried the highest efficacy in the WP group [58].…”

Section: Recent Data On Endoscopic Sleeve Gastroplasty Safety and Eff...mentioning

confidence: 99%

“…Lopez-Nava et al [58] performed redo ESG in 7% of their ESG patients for weight loss failure (WF), weight regain (WR), or weight plateau (WP). R-ESG carried the highest efficacy in the WP group [58]. Mean %TBWL with R-ESG was $16% at 12 months [59].…”

Section: Recent Data On Endoscopic Sleeve Gastroplasty Safety and Eff...mentioning

confidence: 99%

Endobariatrics: well past infancy and maturing rapidly

Shrestha

Shah

2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewThis review summarizes the key developments with regard to FDA-approved endoscopic bariatric metabolic therapies (EBMTs) in the last 2 years.Recent findingsThe prevalence of obesity has increased during the coronavirus disease 2019 (COVID-19) pandemic, and obesity worsens COVID-19 related outcomes. Several studies have confirmed the safety and short-term efficacy of intragastric balloons (IGBs). In the short-term IGBs may improve steatosis and fibrosis in nonalcoholic fatty liver disease and improve quality of life and mental health. Unfortunately weight loss from these temporarily placed devices is not sustained long-term. Endoscopic sleeve gastroplasty (ESG) may be more effective and durable than IGBs, and result in fewer adverse events compared to bariatric surgery. The recently completed MERIT trial may catapult ESG as a first-line EBMT. Aspiration therapy meets safety and effectiveness thresholds for incorporation into routine practice, but overall acceptance has been lower than other FDA-approved EBMTs.SummaryThe field of endobariatrics is rapidly maturing. Significant knowledge gaps remain with regards to combining EBMTs with pharmacologic therapy to improve durability of weight loss. The rapid expansion in the literature supporting safety and long-term efficacy ESG may prompt revision of existing guidelines.

show abstract

Re-suturing after primary endoscopic sleeve gastroplasty (ESG) for obesity

Cited by 27 publications

References 33 publications

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

From surgery to endoscopy: the evolution of the bariatric discipline

Endobariatrics: well past infancy and maturing rapidly

Contact Info

Product

Resources

About